Compare Snowflake Inc (SNOW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs 10X Genomics Inc — how do they compare? Snowflake Inc trades at $357.78 (market cap $121.15B), while 10X Genomics Inc trades at $84.49 (market cap $10.07B). The key difference: Snowflake Inc is far larger — about 12× 10X Genomics Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 54 Days and 10X Genomics Inc for 92 Days on average.
| SNOW | TXG | |
|---|---|---|
Market Cap | $121.15B | $10.07B |
Volume | 3,986,549 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $356.47 | $97.74 |
52-Week Low | $121.11 | $11.48 |
Typical Hold Time | 54 Days | 92 Days |
Enterprise Value | $121.57B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $332.85, down 0.92% on the day, with technical indicators showing a neutral bias amid strong analyst support. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, but continues to post significant net losses (-$1.29 billion). Recent developments include a $3.75 billion convertible note offering and expanded partnerships, positioning the company for future growth in the AI data cloud market.
Snowflake presents a compelling growth story with strong revenue momentum and dominant market positioning, though profitability remains a key challenge. The stock offers 25% upside to the consensus price target of $418.03, supported by overwhelming analyst bullishness (81% buy ratings). However, investors face risks from ongoing losses, high valuation multiples, and competitive pressures in the cloud data sector.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
